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Abstract Expression of the various components of the plasmi- 
nogen activation system is under tight regulation by hormones, 
cytokines, and growth factors under physiologic onditions. Like 
early-response genes, these components are modulated by 
inhibitors of protein synthesis in some cell lines. To clarify the 
specific expression and regulation of mRNAs for urokinase 
(uPA), its receptor (uPAR), and type-I plasminogen activator 
inhibitor (PAI-1), I analyzed RNA from four human cancer cell 
lines by RNA blotting after treatment with eycloheximide, 
anisomycin, emetine or poromycin. These inhibitors, all of which 
induced translational arrest, induced a very diverse response in 
the various transcripts, suggesting that the inhihitors mediate 
their effects through different molecular mechanisms. Dose- 
response analysis howed that, in A549 cells, anisomycin strongly 
induced uPAR and PAI-1 mRNA at concentrations that did not 
cause complete inhibition of protein synthesis, whereas cyclohex- 
imide induced these transcripts in a dose-dependent manner only 
at concentrations ufficient to inhibit total protein synthesis by 
>90%. Puromycin induced the 3.4-kb transcript of PAI-1 
mRNA in A549 and RD cells, whereas it decreased the 
expression of both the 3.4-kb and 2.4-kb PAI-1 transcripts in 
HT-1080 cells. Different time patterns of induction for nPA, 
uPAR and PAI-1 mRNA suggest hat even in the same cell type, 
inhibitors of protein synthesis mediate their effects on various 
genes through different mechanisms. Thus, induction of nPA, 
uPAR and PAI-I transcripts by inhibitors of protein synthesis 
was dependent on the gene, the cell line, and the type of inhibitor, 
and inhibition of protein synthesis per se was not sufficient for 
induction of these transcripts. 
K, V words: Urokinase-type plasminogen activator; Tissue- 
type plasminogen activator; Plasminogen activator inhibitor 
1. Introduction 
~ctivation of the zymogen plasminogen to the active pro- 
tei aase plasmin by urokinase-type plasminogen activator 
(uPA) [1] plays an important role during processes involved 
in the degradation of the extracellular matrix, e.g., during 
w(;und healing, cell migration during trophoblast implanta- 
tion, mammary gland involution, and invasion of cancer cells 
[1, 2]. Activation of plasminogen by tissue-type plasminogen 
aciivator (tPA) is involved in lysis of fibrin clots [3]. The 
*C )rresponding author. Fax: (45)31385450. 
Ab',reviations." uPA, urokinase-type plasminogen activator; tPA, 
tissue-type plasminogen activator; PAI, plasminogen activator inhi- 
bitor; uPAR, urokinase-type lasminogen activator receptor; TGF-13, 
transforming rowth factor-J3; GAPDH, glyceraldehyde 3-phosphate 
debydrogenase; TCA, trichloroacetic a id. 
plasminogen activation process is regulated by two distinct 
and fast-acting specific inhibitors, PAI-1 and PAI-2 [4]. A 
specific and high-affinity receptor for uPA (uPAR) has also 
been identified in all examined cell lines and tissues, although 
the level of expression varies [5]. Binding of uPA to its recep- 
tor strongly enhances the activation of plasminogen, making 
the cell surface an important site for focused proteolysis [6]. 
In vitro the synthesis of the plasminogen activators, the 
inhibitors and the receptor is regulated by a variety of cyto- 
kines, hormones and tumor promoters [1,2,4,7]. In some cell 
lines, treatment with the inhibitor of protein synthesis cyclo- 
heximide transiently induces or increases the level of mRNA 
for uPA [8], tPA [9], PAI-1 [10], PAI-2 [8], and uPAR [11], as 
it does for the normally labile early-response genes [12]. In- 
vestigators have sought to explain this phenomenon by two 
different molecular mechanisms: the presence of specific, 
short-lived mRNA-degrading enzymes, or the existence of la- 
bile repressors that control specific gene transcription [12]. 
According to the second hypothesis, treatment of cells with 
inhibitors of protein synthesis will rapidly decrease the level of 
the repressor molecule within the cells, thereby allowing tran- 
scription of the repressed genes. Although the existence of 
such factors has been postulated for years, labile repressors 
have not yet been biochemically characterized in eukaryotic 
cells. Recent results obtained in C3H 10T1/2 cells, in which 
anisomycin loses its ability to block protein synthesis at con- 
centrations <70 ng/ml, show that at even lower concentra- 
tions anisomycin is still able to induce c-los and c-jun 
mRNA [13,14]. These results are not consistent with a role 
for labile repressor molecules or short-lived specific mRNA- 
degrading enzymes; instead, they suggest direct effects of pro- 
tein synthesis inhibitors on signal transduction pathways for 
c-fos and c-jun [14]. 
The data obtained with protein synthesis inhibitors on the 
various components of the plasminogen activation system 
have all centered on the effects of cycloheximide atconcentra- 
tions that induce complete inhibition of protein synthesis. To 
determine if modulation of uPAR, uPA and PAl-1 mRNA 
expression is a general feature of protein synthesis inhibitors, 
I examined the effects of cycloheximide, anisomycin, emetine 
and puromycin, which mediate their blocking effects on pro- 
tein synthesis through various molecular mechanisms [15], in 
four human cancer cell lines. 
2. Materials and methods 
2.1. Materials 
Cycloheximide, anisomycin, emetine and puromycin were obtained 
from Sigma Chemical Co. (St. Louis, MO). All other materials were 
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Fig. 1. Effects of inhibitors of protein synthesis on uPAR, uPA and PAI-1 mRNA levels in human cell lines (RNA blot analysis). Confluent 
cells were incubated for 6 h under serum-free conditions with buffer alone (lanes 1, 6, 11 and 16), 10 I.tg/ml cycloheximide (lanes 2, 7, 12 and 
17), 250 ng/ml anisomycin (lanes 3, 8, 13 and 18), 10 ktg/ml emetine (lanes 4, 9, 14 and 19), or 50 I.tg/ml puromycin (lanes 5, 10, 15 and 20). 
Cells were harvested, and total RNA was purified as described in section 2. For the RNA blot analysis, 30 ktg of the total RNA was electro- 
phoresed in 1.5% agarose gels under denaturing conditions and blotted onto a nitrocellulose filter. The membrane was hybridized with a ran- 
domly primed 32P-labeled uPAR cDNA probe (A), uPA cDNA probe (B), PAI-1 cDNA probe (C) or GAPDH cDNA probe (D). Cell lines 
are indicated at the top, and positions of the specific mRNA bands are indicated on the right. 
those described previously [11,16] or of the best grade commercially 
available. 
2.2. Cell culture 
The human lung carcinoma cell line A549 (American Type Culture 
Collection CCL 185) and the human rhabdomyosarcoma cellline RD 
(CCL 136) were obtained from Flow Laboratories (Irvine, UK). The 
fibrosarcoma cell lines HT-1080 (CCL 121) and 8387 were obtained 
from A. Vaheri, University of Helsinki, Finland. Approximately 108 
trypsinized cells were seeded into 15-cm petri dishes and grown to 
confluence in Dulbecco's modified Eagle's medium supplemented 
with 10% fetal calf serum, as described previously [17]. Before being 
used for experiments, cells were kept under serum-free conditions for 
48-72 h. The inhibitors were added to the medium for various times 
Table 1 
Summary of effects of treatment with protein synthesis inhibitors on uPAR, uPA and PAI-1 mRNA levels in human cancer cell lines 
mRNA Inhibitor A549 8387 HT-1080 RD 
uPAR Cycloheximide 11.3 ± 2.4 1.9 ± 1.2 1.0 _+ 0.2 6.3 ± 1.4 
Anisomycin 18.4 ± 3.6 4.2 ± 1.9 4.0 ± 1.0 0.9 ± 0.3 
Emetine 8.3 ± 1.8 2.4 ± 1.3 1.3 ± 0.4 1.2 ± 0.7 
Puromycin ND ND 0.4 ± 0.3 0.4 ± 0.3 
uPA Cycloheximide 2.7±1.1 2.4±1.5 0.6±0.4 7.4±1.4 
Anisomycin 3.1±0.8 3.7±1.6 2.1±0.6 1.1±0.4 
Emetine 2.4±1.3 2.6±0.4 1.0±0.2 2.1±0.7 
Puromycin ND 1.1±0.3 0.3±0.3 0.6±0.5 
PAl-1 Cycloheximide 12.4±2.3 4.8±1.1 0.9±0.3 18.4±2.3 
(3.4kb) Anisomycin 15.6±3.4 7.7±0.9 4.6±0.8 7.3±1.3 
Emetine 17.8±1.7 5.1±1.4 1.2±0.4 2.1±1.1 
Puromycin 4.6±0.6 0.8±0.3 0.3±0.2 1.8±0.7 
PAl-1 Cycloheximide 3.4±1.7 4.1±0.5 1.1±0.4 5.7±0.9 
(2.4kb) Anisomycin 3.8±2.3 5.4±0.9 2.1±0.6 2.7±0.4 
Emetine 4.3±1.4 4.7±0.4 1.0±0.3 1.4±0.3 
Puromycin 1.3±0.3 1.0±0.2 0.2±0.3 1.1±0.2 
Numbers represent fold induction (mean+ S.D.) after 6 h treatment, in three independent experiments. The densitometric value obtained for 
samples treated with solvent alone, normalized to the value for GAPDH, has been set to h ND, not detectable. 
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Fig. 2. Dose-dependent effects of anisomycin and cycloheximide on 
the induction of uPAR mRNA and inhibition of total protein 
synthesis in A549 cells. A549 cells were treated with increasing con- 
centrations of anisomycin or cycloheximide for 6 h, and RNA blot 
analysis was performed as described in the legend to Fig. 1. Hybri- 
dization with the uPAR cDNA probe is shown in insets A' and B' 
and rehybridization with the GAPDH probe in insets A" and B". 
The normalized relative amounts of uPAR mRNA are indicated on 
the graph. The uPAR mRNA level in untreated cells was set equal 
to 1, and subsequent points indicate fold induction in treated cells. 
The numbers in the insets indicate untreated cells (lanes 1 and 2) 
and cells treated with anisomycin (A) or cycloheximide (B) at a con- 
centration of 10 ng/ml (lane 3), 50 ng/ml (lane 4), 100 ng/ml (lane 
5), 500 ng/ml (lane 6), 1000 ng/ml (lane 7), or 10000 ng/ml (lane 8). 
Inhibition of total protein synthesis was determined by measuring 
the incorporation of [aSS]methionine into TCA-precipitable proteins. 
Incorporation i  untreated cells was set to 0, and subsequent points 
indicate inhibition in treated cells as a percentage of that in un- 
treated cells. 
and in various concentrations, as indicated for individual experiments. 
Each experiment was performed at least three times, with virtually 
identical results. 
2.3. RNA analysis 
Total RNA was isolated from cells and analyzed by hybridizing 
RNA blots as described previously [16]. The plasmid used as a probe 
for uPAR mRNA (puPAR-1) carries cDNA covering the entire cod- 
ing region and part of the 3'- and part of the 5'-untranslated regions 
[18]. pHuK8 carries a 1.6-kb PstI fragment of the human uPA cDNA 
[19]. A full-length cDNA-probe for PAI-1 was used for detection of 
PAI-1 mRNA [20], and a cDNA for rat glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) [21] was used as a control for equal oading 
and transfer of the RNA samples. Specific signals were quantified by 
scanning of the autoradiographic f lms with a Shimadzu dual-wave- 
length TLC scanner CS-930. Various exposure times were used to 
ensure that the density of the bands on the autoradiographic f lms 
was within the linear range. The relative amounts of uPAR, uPA or 
PAI-I mRNA were normalized against the corresponding relative 
amounts of GAPDH mRNA, which were found to be unaffected by 
treatment of the various inhibitors in A549 cells, as shown in the 
figures for the individual experiments. 
2.4. Metabolic labeling of cells and quantitation fthe labeled prote&s 
The effects of the various inhibitors on total protein synthesis were 
determined by measuring the incorporation of [35S]methionine into 
cellular proteins. The cells were grown to confluence in 35-mm culture 
dishes, washed twice with phosphate-buffered saline, and kept in ser- 
um-free medium for 48 h. At the onset of the experiment, the medium 
was changed, and the inhibitors were added to fresh serum-free med- 
ium 1 h before the addition of [aSS]methionine (50 laCi/ml). After 
incubation for another 5 h the cells were quickly washed twice in 
ice-cold phosphate-buffered saline. The cells were then lysed in 1 ml 
0.1 M Tris, pH 8.1, 10 mM EDTA, 0.5% Triton X-100 and 10 I.tg/ml 
of aprotinin for 15 min and scraped off with a rubber spatula. The 
proteins were precipitated by 7% trichloroacetic acid (TCA), and ali- 
quots were analyzed either by SDS-polyacrylamide g l electrophor- 
esis, followed by autoradiography, or by direct counting in a liquid 
scintillation counter. 
3. Results 
3.1. Cell-specific expression and regulation of uPAR, uPA and 
PAI-1 mRNA by various inhibitors of protein synthesis in 
human cancer cell lines 
Cell-specific expression of uPAR, uPA and PAI-1 mRNA 
and their inducibility by various inhibitors of protein synthesis 
were assessed by RNA blot analysis (Fig. 1). A549 and 8387 
are cell lines with very low or no detectable basal levels of 
uPAR mRNA,  whereas a stronger signal was obtained in HT- 
1080 and RD cells (Fig. 1A). After treatment of the cells with 
various inhibitors of protein synthesis, a diversified picture 
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Fig. 3. Time-dependent ffects of anisomycin and cycloheximide onthe induction of uPAR, uPA and PAI-1 mRNA in A549 cells. Cells were 
cultured, harvested and analyzed by RNA blotting as described in the legend to Fig. 1, except hat the cells were treated with either 25 ng/ml 
anisomycin (A) or 10 ~tg/ml cycloheximide (B) for the times indicated. The membranes were hybridized with a randomly primed 32p-labeled 
uPAR cDNA probe (©), and, after stripping, rehybridized with a uPA cDNA probe (D), a PAI-1 cDNA probe (zx, 3.4 kb; A, 2.4 kb) or a 
GAPDH cDNA probe (o). The relative amounts of uPAR, uPA and PAI-1 mRNA at each time point were estimated by spectrophotometric 
scanning of autoradiograms of the RNA blots hybridized with the uPAR, uPA or PAI-1 probes after normalization against he corresponding 
relative amounts of GAPDH mRNA. mRNA levels at time 0 were set equal to 1, and subsequent points indicate fold induction. The numbers 
in the insets indicate untreated cells (lane 1) and cells treated with either 25 ng/ml of anisomycin or 10 ~tg/ml of cycloheximlde for 1.5 h (lane 
2), 3 h (lane 3), 6 h (lane 4), 9 h (lane 5) or 12 h (lane 6). 
emerges with respect o their effects on specific gene expres- 
sion (Fig. 1A-C). 
In A549 cells, cycloheximide (lane 2), anisomycin (lane 3) 
and emetine (lane 4) strongly induced uPAR mRNA and both 
the 3.4-kb and 2.4-kb PAI-1 transcripts and weakly induced 
uPA mRNA. Puromycin (lane 5) modestly induced only PAI- 
l mRNA. 
In the fibrosarcoma cell lines tested (8387 and HT-1080), 
anisomycin (lanes 8 and 13) induced uPAR, uPA and PAI-1 
mRNA. Cycloheximide had no effect in HT-1080 cells (lane 
12), whereas 8387 cells responded with an increase in both 
PAI-1 and uPA mRNA and a modest increase in uPAR 
mRNA (lane 7). Emetine did not affect any of the mRNAs 
in HT-1080 cells (lane 14) but induced the mRNA levels of 
uPAR, uPA and PAI-1 in 8387 cells (lane 9). Puromycin de- 
creased the basal level of all mRNAs tested in both 8387 and 
HT-1080 cells (lanes 10 and 15). 
In the rhabdomyosarcoma cell line RD, a strong increase in 
uPAR, uPA and PAI-1 mRNA levels was observed after 
treatment with cycloheximide (lane 17), whereas anisomycin 
(lane 18) increased only the level of PAI-1 mRNA; only min- 
or effects, or none, were detected with the other inhibitors. 
Ethidium bromide staining of the gel and blot showed com- 
parative loading of intact RNA for each cell line (data not 
shown), and rehybridization with a GAPDH probe showed 
that the level of GAPDH mRNA was not affected by treat- 
ment with the various inhibitors of protein synthesis n any of 
the cell lines (Fig. 1D). The quantitative r sults of the densi- 
tometric scanning of the autoradiograms of the RNA blots 
are summarized in Table 1. Because the most pronounced 
effects were found with uPAR and PAI-1 mRNA expression 
in A549 cells, this cell line was selected for more detailed 
analysis. 
3.2. Dose-dependent effects of  inhibitors of  protein synthesis on 
synthesis and induction of  uPAR mRNA in A549 cells 
A549 cells were treated with increasing concentrations of 
each of the four inhibitors for 6 h. [3~S]methionine incorpora- 
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ti(~n into TCA-precipitable cellular proteins howed that ani- 
somycin (Fig. 2A), cycloheximide (Fig. 2B), and emetine (data 
not shown) had an almost identical effect on total protein 
sy~thesis: 90% inhibition was achieved at 250 ng/ml. For pur- 
omycin, 2 txg/ml was required for 90% inhibition (data not 
sh,~wn). SDS-polyacrylamide g l electrophoresis of TCA-pre- 
cipitated proteins, followed by autoradiography, showed that 
all the inhibitors blocked synthesis of all labeled proteins in a 
dose-dependent manner (data not shown). 
'qo detectable ffect on the uPAR mRNA level was ob- 
served by concentrations of cycloheximide <500 ng/ml (Fig. 
2I~, inset B', lanes 3-5), whereas higher concentrations caused 
a,  lose-dependent i crease in the uPAR mRNA (lanes 6-8). A 
ve'y different dose-dependent pattern of uPAR mRNA induc- 
tion was observed after treatment with anisomycin: a 9-fold 
in, rease in uPAR mRNA was observed at 10 ng/ml (Fig. 2A, 
in, et A', lane 3), reaching a 25-fold maximum at 100 ng/ml 
(l~,ne 5), followed by a gradual decrease in the response at 
hi:4her concentrations (lanes 6-8). Identical dose-dependent 
in, luction of uPA and PAI-1 mRNA was obtained after cy- 
cl,~heximide and anisomycin treatment (data not shown). In 
ccatrast, puromycin only slightly induced uPAR, uPA and 
P,,I-1 mRNA at very high concentrations (50 and 100 ~tg/ 
m ) (data not shown). 
3. .  Time-dependent effects of  inhibitors of protein synthesis on 
uPAR, uPA and PAI-1 mRNA levels in A549 cells 
Fotal RNA was extracted from untreated A549 cells and 
fr,,m cells treated with each of the inhibitors for various times. 
A~ ter 1.5 h of anisomycin treatment (25 ng/ml), a signal for 
uI"AR was visible and increased to a maximum of 15-fold 
after 3 h of treatment, followed by a slow decline to the basal 
le~ el after 12 h (Fig. 3A). Cycloheximide (10 ~tg/ml) increased 
th : uPAR mRNA level to 15-fold after 6 h, followed by a 
sl,,w decline (Fig. 3B). 
Only a modest effect of anisomycin on uPA mRNA level 
w;s observed for the first 6 h of treatment, followed by a 
mtximal 15-fold increase after 9 h; after cyclohexi mide treat- 
m,;nt a maximal 13-fold increase was observed after 12 h (Fig. 
3F,,B). 
In untreated A549 cells the signal for PAI-1 mRNA was 
b~rely detectable (Fig. 3A,B). After 1.5 h of treatment with 
arisomycin (25 ng/ml), a 5-fold increase in the 3.4-kb tran- 
sc ipt for PAI-1 was detected, whereas no effect on the 2.4-kb 
trz~nscript was detected for up to 3 h of treatment. The level 
fo" both PAI-1 transcripts increased 6- to 7-fold after 6 h, 
fo lowed by a decline. A similar, although more potent, in- 
dtction pattern in the PAI-1 transcripts was observed after 
tr,~atment with 100 ng/ml of anisomycin (data not shown). A 
m ~re potent induction of the 3.4-kb transcript was observed 
at er treatment with cycloheximide for 6 h, and induction 
in:reased for up to 12 h; the 2.4-kb transcript began to in- 
cr ~ase after 9 h (Fig. 3B). 
4. Discussion 
rhe cell-specific and gene-specific effects of four inhibitors 
ol protein synthesis were examined to determine whether in- 
dt~ction of the mRNAs for uPA, uPAR and PAI-1 is a general 
effect related to the blocking of protein synthesis by the in- 
hibitors, or if it can also be caused by other effects of the 
drugs. Cycloheximide acts on the 60S ribosomal subunit to 
inhibit initiation, elongation and termination of protein synth- 
esis and, like emetine and anisomycin, to stabilize polysomes. 
Anisomycin acts on the 60S subunit to block peptide forma- 
tion, and emetine acts on the 40S subunit o block transloca- 
tion. Puromycin is an analog of the 3' end of aminoacyl 
tRNA and degrades polysomes [15]. 
From the results hown in Fig. 1 and Table 1, it is clear that 
inhibition of protein synthesis per se is not sufficient for in- 
duction of the specific mRNA. At concentrations that com- 
pletely blocked protein synthesis, cycloheximide, anisomycin 
and emetine strongly induced the uPAR and PAI-1 mRNA 
levels in A549 cells, whereas puromycin induced a 5-fold in- 
crease only in the 3.4-kb PAI-1 mRNA. The fact that puro- 
mycin did not induce uPAR mRNA in A549 cells shows that 
blocking of protein synthesis is not sufficient for induction of 
a gene that is induced by other inhibitors of protein synthesis. 
In both fibrosarcoma cell lines tested (HT-1080 and 8387), 
cycloheximide did not affect the basal uPAR mRNA level, 
whereas in RD cells it induced a strong increase in uPA, 
uPAR and both PAL1 mRNAs. Generally, the most pro- 
nounced inductive effects were obtained with cycloheximide, 
anisomycin and emetine, whereas only weak inductive or even 
reductive ffects were obtained with puromycin. Although cy- 
cloheximide, anisomycin and emetine all stabilize mRNA by 
trapping it in polysomes, thereby shielding the RNA from 
cytoplasmic ribonucleases, only cycloheximide increased the 
levels of uPA, uPAR and PAI-1 mRNA in RD cells. Thus, 
a very complex and not fully understood induction pattern 
was observed after treatment with the various inhibitors. 
The positive effect of protein synthesis inhibitors is not re- 
stricted to cancer cell lines. Cycloheximide was previously 
found to increase the level of uPAR mRNA in A549, U937 
and HCT116 cells [11,16,22] and the level of PAI-1 mRNA in 
the human fibroblast cell line WI-38 [10]; however, it had no 
effect on the PAI-1 mRNA level in HepG2 cells for up to 12 h 
of treatment [23]. Although cycloheximide treatment for 6 h 
had no effect on PAI-1 mRNA in HT-1080 cells in this study, 
a previous tudy showed a positive effect after 16 h [24], and 
yet another study showed that cycloheximide induced PAI-1 
mRNA in HT-1080 cells within 4~8 h [9]. These results show 
that even in the same cell line, various results can be obtained, 
depending on the source of the cell line. This variability sug- 
gests that cell-specific mechanisms are involved in the induc- 
tion. Cell specificity is further supported by the finding in the 
present study that in A549 cells, cycloheximide, anisomycin 
and emetine all induced uPAR and PAI-1, whereas in RD 
cells, cycloheximide induced uPA, uPAR and PAI-1 mRNA, 
anisomycin induced only PAI-1 mRNA, and emetine had no 
effect. 
As shown in Fig. 2B, cycloheximide increased the uPAR 
mRNA level in a dose-dependent manner only at concentra- 
tions at which -90%o inhibition of protein synthesis was ob- 
served, whereas anisomycin strongly increased uPAR mRNA 
even at a concentration as low as 10 ng/ml, at which only 
partial inhibition of protein synthesis was observed (Fig. 
2A). The maximal effect of anisomycin on uPAR mRNA 
was seen at 100 ng/ml, at which 70% inhibition of total pro- 
tein synthesis was detected. Recent results obtained in C3H 
10T1/2 cells showed that anisomycin, and to a lesser extent 
cycloheximide, but not emetine and puromycin, may act di- 
rectly as an agonist in the phorbol ester and epidermal growth 
factor signal transduction pathway for c-los and c-jun [l 1,12]. 
144 L.R. Lund/FEBS Letters 383 (1996) 139-144 
The results reported here suggest that cycloheximide and ani- 
somycin mediate their effects on the various components of 
the plasminogen activation system in A549 cells through dif- 
ferent mechanisms, although not identical to those described 
for c-fos and c-jun in C3H 10Tl/2 cells; cycloheximide did not 
induce uPAR and PAI-1 mRNA at concentrations <500 ng/ 
ml. It will be interesting to test the effect of protein synthesis 
inhibitors on c-fos and c-jun mRNA expression i  A549 cells. 
Analysis of the time-dependent effects of anisomycin and 
cycloheximide showed that both inhibitors induced a fast and 
potent, although transient, induction of uPAR mRNA, 
whereas their effect on uPA mRNA was delayed, with a max- 
imal effect after 9 or 12 h, respectively. Similarly, the time- 
dependent effects of anisomycin and cycloheximide on PAI-1 
mRNA induction were different. Both inhibitors induced the 
strongest and fastest increase in the 3.4-kb transcript, whereas 
the 2.4-kb transcript increased with slower kinetics, consistent 
with previous reports [10,25]. However, the effect of anisomy- 
cin was transient, with a maximal 6-7-fold effect after 6 h, 
whereas cycloheximide induced a prolonged effect that in- 
creased for at least 12 h. As shown in Fig. 1C and Table 1, 
the strongest increase in all tested cell lines was observed with 
the 3.4-kb transcript of PAI-1, suggesting that the two tran- 
scripts are separately regulated by the various inhibitors of 
protein synthesis, uPA, uPAR, and the 3.4-kb PAI-1 tran- 
script, but not the 2.4-kb transcript, contain an AUUUA- 
rich sequence in the 3' noncoding region that has been found 
in a number of short-lived mRNAs that encode inflammatory 
response mediators [26,27]. This sequence, together with addi- 
tional sequences within the c-fos gene, confers instability to 
the c-fos transcript [28]. In the uPA mRNA, three instability- 
determining sites have been identified in the 3' noncoding 
region [29]. Taken together, these data and the data reported 
here strongly support the idea that inhibitors mediate their 
effects on different genes through different molecular mechan- 
isms. 
Further experiments are needed to elucidate the detailed 
molecular mechanisms by which the inhibitors mediate their 
inductive ffects. Nuclear run-on assays demonstrated only a 
minor effect on the transcription of uPAR, uPA and PAI-1 
genes in A549 cells after treatment with cycloheximide, aniso- 
mycin or emetine (data not shown), whereas cycloheximide 
transiently increased uPA gene transcription i  macrophages 
[30]. In other systems, an increase in mRNA stability has been 
reported after inhibition of protein synthesis [31], but it re- 
mains to be analyzed if the inhibitors have a similar effect on 
uPA, uPAR and PAI-1 mRNA. 
In summary, it was found that induction of uPA, uPAR 
and PAI-1 mRNA by inhibitors of protein synthesis was de- 
pendent on the gene, the cell line and the type of inhibitor. 
Furthermore, inhibition of protein synthesis per se was not 
sufficient for induction. Further studies are needed to eluci- 
date the detailed molecular mechanisms underlying the induc- 
tion, or lack of induction of specific genes by protein synthesis 
inhibitors. 
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